Michelle Monje, MD, PhD
Michelle Monje, MD, PhD joined the faculty at Stanford University in 2011 as an Assistant Professor of Neurology & Neurological Sciences. Following her undergraduate degree in biology at Vassar College, Dr. Monje received her MD and PhD in Neuroscience from Stanford University. She then compl
Gerald Grant, MD, FACS
Gerald Grant, MD, FACS directs the Blood-brain Barrier Translational Laboratory, focusing on enhancing drug delivery to brain tumors in children.Dr. Grant received his MD from Stanford University in 1994 and trained as a resident in neurosurgery at the University of Washington Medical Cent
Sonia Partap, MD
Sonia Partap, MD, is Clinical Associate Professor of Neurology & Neurological Sciences and of Pediatrics at Stanford University, and a neuro-oncologist at Lucile Packard Children’s Hospital Stanford. Dr. Partap received both her B.A. and M.D. at the University of Missouri, Kansas City, before
Lucile Packard Children’s Hospital Stanford opened in 1991 and is the heart and soul of Stanford Children’s Health. Nationally ranked and internationally recognized, the 361-bed hospital located in Palo Alto, Calif. is devoted entirely to pediatrics and obstetrics.
The Pediatric Neuro-Oncology program at Packard Children’s includes world-class pediatric neurosurgeons, neuro-radiologists, radiation oncologists, neuro-oncologists, neuropathologists, social workers, neuropsychologists, rehabilitation experts and nurse practitioners.
Packard Children’s experts specialize in surgical techniques that reduce exposure of the brain or spinal column, lower risk, shorten recovery time, and minimize the disruption of healthy tissue. Packard Children’s was also the first hospital in Northern California to deploy ROSA™, the robotic surgical assistant, for pediatric use. ROSA™ makes neurosurgery safer, faster, and more precise.
Researchers at the Stanford University School of Medicine and Packard Children’s are investigating ways to deliver new chemotherapy drugs directly to brain tumors. One such effort, led by CBTTC investigator Dr. Gerald Grant, examines ways to get different kinds of drugs past the blood-brain barrier, the gate-keeping mechanism that keeps dangerous molecules (and potentially helpful drugs) out of the brain. Dr. Grant’s work may open doors to whole new kinds of chemotherapeutic drugs.
Stanford is currently running more than a dozen brain-tumor-related clinical trials, including studies of new immune therapies and chemotherapy drugs, innovative combinations of chemotherapy and radiation, and new medications that may help address the memory and attention problems that patients sometimes experience after treatment.
Supporters may be familiar with Dr. Michelle Monje, who works at this institution. Her work centers on high grade gliomas; predominantly DIPG. She is also currently running a CAR-T trial.
Anthony Bet | Clinical Research Coordinatorhttps://www.stanfordchildrens.org/